Apnimed

We asked 1,500 people with obstructive sleep apnea (OSA) about the unseen burdens and challenges of living with the disease as part of our Sleep Health Inquiries on Needs and Emotions (SHINE) survey.     The largest survey of its kind conducted to understand the psychosocial impact of OSA to date, the SHINE survey revealed that OSA impacts almost every aspect of a person’s life, including their relationships, work productivity, mental health, and more.    However, this effort is about more than data—it’s about amplifying the voices of those impacted by OSA and ensuring the unmet needs of this community receive the attention they deserve. Discover the full results and access our resources now at https://bit.ly/3Y1zo4y.    We are grateful to all survey participants who shared their personal OSA journeys as well as the national advocacy organizations we consulted to ensure the survey and its analysis accurately represented the experiences and viewpoints of the diverse OSA community, including: Alliance of Sleep Apnea Partners, American Sleep Apnea Association, and Project Sleep.    #OSA #SleepApnea #SleepHealth #ObstructiveSleepApnea 

OSA impacts more than just sleep. With 92% of those affected reporting struggles with productivity and 62% saying it holds them back in their careers, it's clear that untreated OSA can impact an organization’s overall health and success. John Cronin, MD SVP of Clinical Development shares how HR leaders can support employees affected by OSA and boost overall workforce health and performance. Read the full article: https://lnkd.in/ebq3WEQ2 #OSA #SleepHealth #HR #EmployeeWellbeing #Apnimed #WorkplaceWellness

We’re thrilled to announce the addition of two biopharma industry veterans to the Apnimed team! Ramzi Benamar joins us as Chief Financial Officer, and Gary Sender has been appointed to our Board of Directors, where he will serve as Chair of the Finance Committee. Ramzi and Gary bring a wealth of leadership experience and a shared commitment to addressing critical unmet medical needs. We’re excited about the impact they’ll have as we continue to advance our mission of transforming the future of OSA treatment. Learn more about their appointments and our vision here:: https://lnkd.in/gJpfQcGX #sleepapnea #leadership #healthcare #innovation #OSA #biotech

Navigating the daily and long-term challenges of obstructive sleep apnea (OSA) can be an uphill battle. Miranda Chappel-Farley, PhD, has embraced and challenged that climb, and encourages others to do the same.     Diagnosed at age 21, Miranda now works to raise awareness of OSA and reduce stigma by sharing her story as both a patient and a sleep neuroscientist.    Learn more about Miranda’s OSA story and get perspectives from others who live with the disease in our Sleep Health Inquiries on Needs and Emotions (SHINE) survey: https://bit.ly/4f7Z3je     #OSA #SleepApnea #SleepHealth #ObstructiveSleepApnea 

🧠 Today is World Mental Health Day, and we’re shining a light on the often-overlooked connection between mental health and obstructive sleep apnea (OSA). According to the SHINE survey, 67% of people with OSA reported feeling depressed or hopeless, and 71% said they struggle with daily stress. It’s no wonder—lack of sleep makes everything harder, including staying positive! 😴 Let’s break the stigma and support those living with #OSA. Learn more about the SHINE survey results at OSASurvey.com. 💙 #WorldMentalHealthDay #OSASurvey #SleepHealth #MentalHealth

Couldn't be more proud of our mighty team for this milestone!

We are thrilled to announce the early completion of patient enrollment for our SynAIRgy Phase 3 study of AD109, our investigational oral treatment for obstructive sleep apnea (OSA). 🎉 A heartfelt thank you to all the patients who are participating in this crucial trial and to the dedicated staff at our trial sites. Your commitment is bringing us closer to potentially redefining the standard of care for OSA. We know more treatment options are desperately needed. AD109 aims to address the root cause of OSA, and our mission is to make it become the first FDA-approved oral therapy to enhance oxygenation and improve patient outcomes. Stay tuned for more updates as we continue on this journey to transform OSA treatment. #OSA #SleepApnea #AD109 #ClinicalTrials

Our team will present our latest study findings on the prevalence of obesity hypoventilation syndrome (OHS) at #ERSCongress. Join us for our poster presentation on Sunday, September 8 at 8 a.m. CEST. We look forward to engaging with fellow respiratory experts and hearing the latest perspectives and findings in respiratory medicine and science.    Learn more: https://lnkd.in/g6aFtcFx

Help us welcome Chasty Daniels, MA as our new Principal Clinical Trial Manager. Chasty comes to us with over a decade of experience ranging from research operations assistance to global trial management and will help build and maintain Apnimed clinical trials. Welcome aboard, Chasty!  Explore careers at Apnimed. https://bit.ly/4dO72Bt

We’re thrilled to share Michele Miller, PharmD has joined our team as Director, Medical Information. With over a decade of experience in the field, Michele will play a key role in elevating relationships with health care personnel and the patient experience while building a best-in-industry Medical Information capability at Apnimed. Welcome, Michele! Interested in working with us? Explore more Apnimed careers. https://bit.ly/4dO72Bt